Geiparvarin 是一种抗癌剂和 MAO-B 抑制剂(pIC50 = 6.84 μM),通过下调 COX2 表达抑制血管生成、阻滞细胞周期于 G1 期并诱导癌细胞凋亡(Apoptosis),同时具有抗微管活性(Microtubule/Tubulin)并可破坏细胞骨架以发挥抗增殖作用,对肺癌、白血病和乳腺癌具有研究意义。
产品编号: MS-X03770 CAS No.: 36413-91-9 分子式: C19H18O5 分子量: 326.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Geiparvarin 是一种抗癌剂和 MAO-B 抑制剂(pIC50 = 6.84 μM),通过下调 COX2 表达抑制血管生成、阻滞细胞周期于 G1 期并诱导癌细胞凋亡(Apoptosis),同时具有抗微管活性(Microtubule/Tubulin)并可破坏细胞骨架以发挥抗增殖作用,对肺癌、白血病和乳腺癌具有研究意义。

生物实验数据

生物活性 Geiparvarin is an anticancer agent and MAO-B inhibitor (pIC50 = 6.84 μM) that exerts antitumor effects by downregulating COX2 expression to inhibit angiogenesis, induces G1 phase cell cycle arrest and apoptosis in cancer cells, and exhibits anti-microtubule activity (Microtubule/Tubulin) and cytoskeleton disruption to exert antiproliferative effects, showing research significance for lung cancer, leukemia, and breast cancer.
IC50 & Target MAO-B:6.84 μM (pIC50)
体外研究
(In Vitro)

Geiparvarin (Compound 8) (72 h) (48 h) 对人类多种肿瘤细胞系的增值有抑制作用 (IC50: 5.7 μM for SHSY5Y, 6.3 μM for HL-60, 9.2 μM for K562, 9.8 μM for HT-1080, 11.5 μM for A-549)。

Geiparvarin (8 μM, 24-72 h) 阻滞 HL-60 细胞周期于 G1 期,诱导非 caspase 依赖性凋亡。

Geiparvarin (72 h) 对耐药细胞系均显示出完全抑制作用,不受介导抗肿瘤药物外排的转运蛋白的影响。

Geiparvarin (1 μM, 24 h) 在 HOS 和 143B 细胞中抑制其侵袭能力。

Geiparvarin (0.5-2 μM, 24-48 h) 在 HOS 和 143B 细胞中激活凋亡通路,抑制 COX2 及下游血管生成通路,诱导 caspase 依赖性凋亡。

Geiparvarin 在骨肉瘤细胞中依赖 COX2 下调发挥抗肿瘤作用,COX2 过表达逆转其对增殖和侵袭的抑制。

Geiparvarin (10 μM, 24 h) 在 Balb/c 3T3 成纤维细胞中破坏细胞骨架,尤其是中间丝。

Geiparvarin (0.01-10 μM) 在鼠肝线粒体提取的 MAO-B 中,抑制率随浓度升高显著增加 pIC50 = 6.84 (IC50 = 1.45 μM)。

Cell Viability Assay

Cell Line: K562 cells, HL-60 cells, HT-1080 cells, A-549 cells, SHSY5Y cells, CEM cells, CEM/Vbl100 cells, LoVo cells, LoVo/Doxo cells;
Concentration:
Incubation Time: 72 h
Result: Had an IC50 range of 5.7 μM-11.5 μM in human tumor cell lines.

Cell Cytotoxicity Assay

Cell Line: L02 cells, A-549 cells, HeLa cells, QGY-7701 cells, SW480 cells, SGC7901 cells, MDA-MB-231 cells
Concentration:
Incubation Time: 48 h
Result: Had significant inhibitory activity against a variety of cancer cells (such as SGC7901: IC₅₀=7.59 μM; HeLa: IC₅₀=9.09 μM) and had low toxicity to normal liver cells L02 (IC₅₀>300 μM).
Ranged in IC₅₀ values of cells after treatment: 7.59-20.34 μM.

Apoptosis Analysis

Cell Line: HOS Cells, 143B Cells, HL-60 cells
Concentration: 0.5 μM, 1 μM, 2 μM for HOS Cells and 143B Cells 8 μM for HL-60 cells
Incubation Time: 24 h, 48 h for HOS Cells and 143B Cells; 72 h for HL-60 cells
Result: Significantly increased Caspase-3 enzyme activity.
Reduced the proportion of G1 phase cells from 43.7 % to S phase cells from 34.8 % after 72 hours.
Induced DNA fragmentation in HL-60 cells.
Caused chromatin condensation and apoptotic body formation in HL-60 cells, as observed by electron microscopy.

Cell Invasion Assay

Cell Line: HOS Cells, 143B Cells
Concentration: 1 μM
Incubation Time: 24 h
Result: Significantly reduced the number of cells penetrating the membrane.

Western Blot Analysis

Cell Line: HOS Cells, 143B Cells
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 24 h, 48 h
Result: Down-regulated COX2, VEGF, CD31 (angiogenesis-related proteins) and up-regulated cleaved PARP/caspase-3 (apoptosis proteins).

Immunofluorescence

Cell Line: Balb/c 3T3 fibroblasts
Concentration: 10 μM
Incubation Time: 24 h
Result: Slightly shortened microfilaments and reduced their density, inhibited microtubule polymerization, and caused the intermediate filament vimentin to reorganize into short fibers and accumulate around the nucleus.
体内研究
(In Vivo)

Geiparvarin (Compound 8) (0.5 mg/kg, i.p, 每三天持续数周/每天) 在裸鼠的 143B/9901 细胞异种移植瘤模型中抑制肿瘤生长和肺转移,无显著毒性。

Animal Model: 143B/9901 cells xenograft tumor model in female nude mice (6 weeks)
Dosage: 0.5 mg/kg
Administration: Intraperitoneal injection (i.p.), every 3 days for several weeks; Intraperitoneal injection (i.p.),every day (for safety assessment)
Result: Significantly reduced the tumor volume and weight of the subcutaneous transplanted tumor model, and increased the apoptotic cells in the tumor tissue.
Inhibited the growth of primary tumors and lung metastasis, and reduced the number and size of lung metastatic nodules.
Increased the weight of mice, and there was no pathological damage to major organs.

化学信息

分子量 326.34
分子式 C19H18O5
CAS No. 36413-91-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础